The Future of Patient Care in RRMM
Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.
EP: 1.Case Presentation: A 71-Year-Old Woman with Relapsed/Refractory Multiple Myeloma (RRMM)
EP: 2.Available Treatments for Patients With RRMM After 4+ Prior Lines of Therapy
EP: 3.Talquetamab in Patients With RRMM: Key Takeaways From MontumenTAL-1
EP: 4.Emerging Treatments for Patients With RRMM: Data From CARTITUDE-1
EP: 5.Toxicity Management for Emerging Bispecifics in Patients With RRMM
EP: 6.The Future of Patient Care in RRMM
Positive Isa-VRd Trials in Transplant-Ineligible Myeloma Show New Approach
September 17th 2024During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series.
Read More
Sequencing of Cell Therapies in Multiple Myeloma Continues Evolving
September 10th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed how to implement use of bispecific T-cell engagers in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Lower-Intensity Talquetamab Dose Shows Potential in Multiple Myeloma
August 30th 2024During a Case-Based Roundtable® event, Tara K. Gregory, MD, discussed the MonumenTAL-1 trial of talquetamab in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
